CJC-1295
Description
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to release growth hormone through activation of the GHRH receptor. Developed by ConjuChem Biotechnologies, this 29-amino acid peptide features four amino acid substitutions at positions 2, 8, 15, and 27 that dramatically enhance its resistance to enzymatic degradation compared to native GHRH. The tetrasubstituted structure extends plasma half-life from minutes to approximately 30 minutes for the standard form, and when conjugated with Drug Affinity Complex (DAC), the half-life extends to approximately 6-8 days by binding to serum albumin. CJC-1295 has been extensively studied in clinical trials for growth hormone deficiency, lipodystrophy, and age-related decline in GH levels. Unlike direct GH administration, CJC-1295 preserves the body's natural pulsatile GH secretion pattern, maintaining feedback regulation and potentially offering a more physiological approach to GH optimization.
Certificate of Analysis
Every batch of CJC-1295 is independently lab-tested to a minimum of 98% purity. A Certificate of Analysis is available on request — contact us with your order or lot number and we'll send the COA for your specific batch.
Request a COAFor laboratory and research use only. Minimum 98% purity. Supplied in sterile, flip-top headspace vials for laboratory use. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. The purchaser accepts full responsibility for safe handling, storage and lawful use.